Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry
- PMID: 28232409
- DOI: 10.1183/13993003.01592-2016
Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry
Erratum in
-
"Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry." Helen E. Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M.A. Hopkins, Yuben Moodley, Paul N. Reynolds, Sally Chapman, E. Haydn Walters, Christopher Zappala, Heather Allan, Gregory J. Keir, Andrew Hayen, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Sacha Macansh and Tamera J. Corte. Eur Respir J 2017; 49: 1651592.Eur Respir J. 2017 Mar 29;49(3):1651592. doi: 10.1183/13993003.51592-2016. Print 2017 Mar. Eur Respir J. 2017. PMID: 28356377 No abstract available.
Abstract
7The prevalence of idiopathic pulmonary fibrosis (IPF), a fatal and progressive lung disease, is estimated at 1.25-63 out of 100 000, making large population studies difficult. Recently, the need for large longitudinal registries to study IPF has been recognised.The Australian IPF Registry (AIPFR) is a national registry collating comprehensive longitudinal data of IPF patients across Australia. We explored the characteristics of this IPF cohort and the effect of demographic and physiological parameters and specific management on mortality.Participants in the AIPFR (n=647, mean age 70.9±8.5 years, 67.7% male, median follow up 2 years, range 6 months-4.5 years) displayed a wide range of age, disease severity and co-morbidities that is not present in clinical trial cohorts. The cumulative mortality rate in year one, two, three and four was 5%, 24%, 37% and 44% respectively. Baseline lung function (forced vital capacity, diffusing capacity of the lung for carbon monoxide, composite physiological index) and GAP (gender, age, physiology) stage (hazard ratio 4.64, 95% CI 3.33-6.47, p<0.001) were strong predictors of mortality. Patients receiving anti-fibrotic medications had better survival (hazard ratio 0.56, 95% CI 0.34-0.92, p=0.022) than those not on anti-fibrotic medications, independent of underlying disease severity.The AIPFR provides important insights into the understanding of the natural history and clinical management of IPF.
Copyright ©ERS 2017.
Comment in
-
The yin and yang of idiopathic pulmonary fibrosis.Eur Respir J. 2017 Feb 23;49(2):1602316. doi: 10.1183/13993003.02316-2016. Print 2017 Feb. Eur Respir J. 2017. PMID: 28232416 No abstract available.
Similar articles
-
Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.BMC Pulm Med. 2018 Jan 25;18(1):19. doi: 10.1186/s12890-018-0575-y. BMC Pulm Med. 2018. PMID: 29370786 Free PMC article.
-
Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.Respir Res. 2021 Feb 5;22(1):40. doi: 10.1186/s12931-021-01634-x. Respir Res. 2021. PMID: 33546682 Free PMC article.
-
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC. Ann Am Thorac Soc. 2017. PMID: 28388260
-
A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.Dan Med J. 2015 Apr;62(4):B5069. Dan Med J. 2015. PMID: 25872544 Review.
-
[Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry].Dtsch Med Wochenschr. 2012 Dec;137(49):2586-8. doi: 10.1055/s-0032-1327244. Epub 2012 Nov 27. Dtsch Med Wochenschr. 2012. PMID: 23188642 Review. German.
Cited by
-
National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care.BMJ Open Respir Res. 2022 Sep;9(1):e001363. doi: 10.1136/bmjresp-2022-001363. BMJ Open Respir Res. 2022. PMID: 36571594 Free PMC article.
-
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.Respir Res. 2020 Jan 6;21(1):7. doi: 10.1186/s12931-019-1269-6. Respir Res. 2020. PMID: 31906942 Free PMC article. Review.
-
Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden.BMC Pulm Med. 2019 Nov 27;19(1):222. doi: 10.1186/s12890-019-0994-4. BMC Pulm Med. 2019. PMID: 31771560 Free PMC article.
-
Exposure to PM2.5 is a risk factor for acute exacerbation of surgically diagnosed idiopathic pulmonary fibrosis: a case-control study.Respir Res. 2021 Mar 12;22(1):80. doi: 10.1186/s12931-021-01671-6. Respir Res. 2021. PMID: 33711988 Free PMC article.
-
Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study.BMJ Open Respir Res. 2019 Jun 21;6(1):e000443. doi: 10.1136/bmjresp-2019-000443. eCollection 2019. BMJ Open Respir Res. 2019. PMID: 31321059 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous